Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onvatilimab - Immunext

Next Previous
Drug Profile

Onvatilimab - Immunext

Alternative Names: anti-VISTA antibody; CI 8993; JNJ 61610588

Latest Information Update: 21 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuNext
  • Developer Curis; ImmuNext; Janssen Research & Development
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Jan 2024 Option and license agreement between Curis and ImmuNext expires for VISTA antagonizing compounds, including CI 8993 in January 2024
  • 19 May 2023 Curis completes a phase I trial in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Australia and USA (IV) (NCT04475523)
  • 31 Dec 2022 Immunext has patent protection for anti-VISTA antibodies including onvatilimab in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top